Global Alpha-1 Antitrypsin Deficiency Disease Market Size, Share, Trends, Opportunity & Forecast, 2020-2030

The Alpha-1 Antitrypsin Deficiency Disease market is expected to reach $3.53 Billion by 2030, growing at a CAGR of 7.82%. The market is driven by an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Key players include Shire, GSK, CSL Behring, AstraZeneca, Grifols, Teva Pharma, Boehringer Ingelheim, Kamada, and Pfizer.